

REMARKS

Entry of the foregoing, reexamination and further and favorable consideration of the subject application in light of the following remarks, pursuant to and consistent with 37 C.F.R. § 1.112, are respectfully requested.

I. Amendments to the Claims

By the foregoing amendments, the specification has been amended to incorporate Reference Numbers 1-6 into the description. Additionally, Claims 2-4 have been amended to be in independent form. Claim 7 has been amended to recite definitions of R and Q found in the specification. Claims 1 and 17-20 have been canceled. The amendments to the claims have been made without prejudice or disclaimer to any subject matter recited or canceled herein. Applicants reserve the right to file one or more continuation and/or divisional applications directed to any canceled subject matter. No new matter has been added.

II. Response to Objection to the Drawings

The Examiner has objected to the drawings for failing to comply with 37 CFR 1.84(p)(5) because Figures 1-2 contain Reference Numerals 1-6 which were not mentioned in the description.

Accordingly, the appropriate references to the numerals have been inserted into the attached Substitute Specification. The Specification has been amended to name the compounds illustrated in Fig. 2 so that the reference numerals 4-6 could be inserted into the specification. As the named compounds and synthesis scheme are illustrated in Figure 2, the amendment does not introduce new matter.

III. Response to Claim Rejections Under 35 U.S.C. § 112, Second Paragraph

Claims 7-20 stand rejected under 35 U.S.C. § 112, second paragraph, as allegedly being indefinite for failing to point out and distinctly claim the subject matter which applicant

regards as the invention. The Examiner contends that the meaning of R and Q are unclear. R and Q are described at pages 2 and 6-7 of the application. Definitions of R and Q found there are now recited in claim 7. Thus, the rejection can not be reasonably asserted against the claims as amended.

IV. Response to Claim Rejection Under 35 U.S.C. § 103(a)

A. Claims 1 and 20 stand rejected under 35 U.S.C. § 103(a) as purportedly unpatentable over Miller et al. (U.S. Patent No. 6,471,942). Without acceding to the rejection, claims 1 and 20 have been canceled thereby rendering the rejection moot.

B. Claims 5-6 stand rejected under 35 U.S.C. § 103(a) as purportedly unpatentable over Miller et al. (U.S. Patent No. 6,471,942) in further view of Tabata et al. (Biological functions of fullerene, Pure Appl. Chem 1999; 71(11) 2047-2053. Without acceding to the rejection, claims 5 and 6 have been canceled thereby rendering the rejection moot.

V. Allowable Subject Matter

The Examiner has indicated that claims 2-4 would be allowable if rewritten in independent form including all the limitations of the base claim and any intervening claims.

Accordingly, claims 2-4 have been rewritten to be in independent form. Moreover, claims 7-16 were not subject to any prior art rejection. Thus, it is believed that claims 7-16 should also be allowable.

VI. Conclusion

In view of the foregoing, further and favorable action in the form of a Notice of Allowance is believed to be next in order. Such action is earnestly solicited.

In the event that there are any questions related to this Amendment and Reply, or the application in general, it would be appreciated if the Examiner would telephone the

undersigned attorney at the below-listed telephone number concerning such questions so that prosecution of this application may be expedited.

Respectfully submitted,

BUCHANAN INGERSOLL & ROONEY PC

Date: October 21, 2010

By: /Christopher L. North/
Christopher L. North
Registration No. 50433

Customer No. 21839
703 836 6620